Innodem and Novartis to Test Eye-tracking Technology & Managing Certain MS Accidents episode artwork

EPISODE · Jan 10, 2022 · 9 MIN

Innodem and Novartis to Test Eye-tracking Technology & Managing Certain MS Accidents

from MS News & Perspectives · host MS News Today

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how Innodem and Novartis Canada are launching a clinical trial to evaluate biomarker eye-tracking technology for monitoring MS progression.Plus, Price reads “My Coffee Cup Runneth Over, Plus a Darned Interruption”, a column by John Connor.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/ =====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/

Episode metadata supplied by the publisher feed · Published Jan 10, 2022

Embed this episode

NOW PLAYING

Innodem and Novartis to Test Eye-tracking Technology & Managing Certain MS Accidents

0:00 9:30

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MS News & Perspectives?

This episode is 9 minutes long.

When was this MS News & Perspectives episode published?

This episode was published on January 10, 2022.

Can I download this MS News & Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!